The trial was terminated early following a futility analysis, but there was a numerical trend favoring birtamimab in the analysis of the primary composite end point of all-cause mortality and cardiovascular hospitalization in the overall population and it was hypothesized to be driven by a treatment effect in the most advanced patients (Mayo stage IV).
← all excerpts
Recent developments in systemic light-chain amyloidosis prognosis and treatment.
1
—
—